| Ytd | 224.27% | |
| 1y | 408.50% |
| Open | 30.93 | Prev Close | 31.26 | Low | 28.70 | High | 31.29 | Mkt Cap | 4.68B |
| Vol | 4.36M | Avg Vol | 4.20M | EPS | -0.83 | P/E | N/A | Forward P/E | -18.18 |
| Beta | 1.19 | Short Ratio | 7.02 | Inst. Own | 114.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 25.38 | 200-d Avg | 15.28 | 1yr Est | 43.82 |
Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and r
Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and r
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Bu
AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.
Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company com
US stocks rose with Nasdaq up 400 points. Dow up 0.32%, Nasdaq up 1.55%, S&P 500 up 0.94%. Tech
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat c
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with v